June 28, 2023: Kingsray Biosciences Incorporated (Kingsray), a leading global provider of life sciences research, development and manufacturing services, recently completed a domestic plant expansion of more than 37,000 square meters, expanding its cGMP production capacity for sgRNA and non-viral DNA drug vectors. The expansion doubles Kingsley's drug vector capacity, enabling rapid delivery of high-quality ingredients to biopharmaceutical companies and gene cell therapy (GCT) drug discovery startups, which will help advance novel therapies from research to clinical translation and accelerate time-to-market.

As a market leader in cGMP-grade CRISPR sgRNA and HDR (homologous recombination repair) template synthesis, through this capacity expansion, Kingsley Biologics will be able to shorten the waiting time for critical genetic material in GCT and reduce the significant financial risk for such therapy development companies. Meanwhile, Kingsley has extensive program experience in cGMP-grade sgRNA and non-viral DNA drug vectors, complete batch records, documentation, and regulatory support for GCT development and IND filings.

June 28, 2023: Kingsray Biosciences Incorporated (Kingsray), a leading global provider of life sciences research, development and manufacturing services, recently completed a domestic plant expansion of more than 37,000 square meters, expanding its cGMP production capacity for sgRNA and non-viral DNA drug vectors. The expansion doubles Kingsley's drug vector capacity, enabling rapid delivery of high-quality ingredients to biopharmaceutical companies and gene cell therapy (GCT) drug discovery startups, which will help advance novel therapies from research to clinical translation and accelerate time-to-market.

As a market leader in cGMP-grade CRISPR sgRNA and HDR (homologous recombination repair) template synthesis, through this capacity expansion, Kingsley Biologics will be able to shorten the waiting time for critical genetic material in GCT and reduce the significant financial risk for such therapy development companies. Meanwhile, Kingsley has extensive program experience in cGMP-grade sgRNA and non-viral DNA drug vectors, complete batch records, documentation, and regulatory support for GCT development and IND filings.

June 28, 2023: Kingsray Biosciences Incorporated (Kingsray), a leading global provider of life sciences research, development and manufacturing services, recently completed a domestic plant expansion of more than 37,000 square meters, expanding its cGMP production capacity for sgRNA and non-viral DNA drug vectors. The expansion doubles Kingsley's drug vector capacity, enabling rapid delivery of high-quality ingredients to biopharmaceutical companies and gene cell therapy (GCT) drug discovery startups, which will help advance novel therapies from research to clinical translation and accelerate time-to-market.

As a market leader in cGMP-grade CRISPR sgRNA and HDR (homologous recombination repair) template synthesis, through this capacity expansion, Kingsley Biologics will be able to shorten the waiting time for critical genetic material in GCT and reduce the significant financial risk for such therapy development companies. Meanwhile, Kingsley has extensive program experience in cGMP-grade sgRNA and non-viral DNA drug vectors, complete batch records, documentation, and regulatory support for GCT development and IND filings.

June 28, 2023: Kingsray Biosciences Incorporated (Kingsray), a leading global provider of life sciences research, development and manufacturing services, recently completed a domestic plant expansion of more than 37,000 square meters, expanding its cGMP production capacity for sgRNA and non-viral DNA drug vectors. The expansion doubles Kingsley's drug vector capacity, enabling rapid delivery of high-quality ingredients to biopharmaceutical companies and gene cell therapy (GCT) drug discovery startups, which will help advance novel therapies from research to clinical translation and accelerate time-to-market.

As a market leader in cGMP-grade CRISPR sgRNA and HDR (homologous recombination repair) template synthesis, through this capacity expansion, Kingsley Biologics will be able to shorten the waiting time for critical genetic material in GCT and reduce the significant financial risk for such therapy development companies. Meanwhile, Kingsley has extensive program experience in cGMP-grade sgRNA and non-viral DNA drug vectors, complete batch records, documentation, and regulatory support for GCT development and IND filings.